FibroGen Reports First Quarter 2024 Financial Results
Expect approval decision for roxadustat in chemotherapy-induced anemia (CIA) in China in the second half of 2024.
- Expect approval decision for roxadustat in chemotherapy-induced anemia (CIA) in China in the second half of 2024.
- Total revenue for the first quarter of 2024 was $55.9 million, as compared to $36.2 million for the first quarter of 2023, an increase of 55% year over year.
- At March 31, 2024, FibroGen reported $214.7 million in cash - defined as cash, cash equivalents, investments, and accounts receivable.
- FibroGen will host a conference call and webcast today, Monday, May 6, 2024, at 5:00 PM Eastern Time to discuss financial results and provide a business update.